Cipher Pharma Launches A Foam Preparation Of Bionect
- Offers Dermatologists a New Formulation of Leading Topical Product with Low Molecular Weight Hyaluronic Acid -
- Bionect® Foam Improves Ease of Treatment Through an Advantageous Vehicle for Hard-to-Reach Dermal Ulcers, Wounds, Burns, and other Skin Conditions, Especially in Hair-Bearing Areas1 -
CHARLESTON, S.C.--(BUSINESS WIRE)--Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that its prescription topical Bionect® is now available in the United States in a lightweight foam preparation that holds its shape until application, making it easier for dermatologists to treat hard-to-reach skin areas. Foams have cosmetic advantages, and are known to be well-suited for hair-bearing areas.1
“We are excited to bring another innovative product to the dermatology community with the expansion of our Bionect® franchise of topical treatments which safely and effectively manage inflammation, discomfort and redness associated with irritations of the skin”
“We are excited to bring another innovative product to the dermatology community with the expansion of our Bionect® franchise of topical treatments which safely and effectively manage inflammation, discomfort and redness associated with irritations of the skin,” said Charles F. Jenkins, Vice President of Marketing, Cipher US. “Bionect as a foam, coupled with the benefits of Low Molecular Weight Hyaluronic Acid, gives dermatologists better access to more of the skin's surface.”
Bionect® Foam has the same moisturizing and healing properties of Bionect® cream and gel. It features Low Molecular Weight Hyaluronic Acid, which is naturally present in the skin and has been shown in studies to reduce signs and symptoms of inflammation and stimulate healing. As a non-steroidal, Bionect® Foam is especially well-suited for safely dressing and managing dermal ulcers, wounds, post-operative incisions, first- and second-degree burns and other skin irritations. It also gives dermatologists and their patients a non-abrasive foam option for hard-to-reach places such as hair-bearing areas and skin folds.
Bionect® Foam comes in a foam canister and is available by prescription only. The Bionect® Patient Access Card is available to help patients who need assistance paying for out-of-pocket medication costs. For more information about the co-pay card, patients can speak with their dermatologist or healthcare provider or visit www.bionect.com.
For complete Bionect® Foam prescribing information visit www.bionect.com.
Benefits of Low Molecular Weight Hyaluronic Acid
Low molecular weight hyaluronic acid, found in all Bionect® products, is a substance that is naturally present in the skin and other parts of the body. One of the crucial functions of hyaluronic acid is to attract and hold up to 1,000 times its weight in water. This allows for the transport of proteins, oxygen and nutrients through the skin and helps maintain an intact dermal matrix structure. Recent investigations have also shown that, in addition to its water-binding properties, hyaluronic acid also plays a central role in the inflammation and tissue repair process.2
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (NASDAQ:CPHR; TSX:CPH) is a rapidly-growing specialty pharmaceutical dermatology company with a diversified portfolio of commercial-stage products. Cipher aims to become the most customer-centric dermatology company in North America.
Cipher completed seven transactions in 2015, including the acquisition of Innocutis and its nine branded dermatology products, to build its U.S. commercial presence, expand its Canadian dermatology franchise and broaden its pipeline. Cipher is well-capitalized to drive long-term, sustained earnings growth by leveraging its proven clinical development capabilities and efficient commercial execution. For more information, visit www.cipherpharma.com.
1 Ledwohl, M. , et al. “A randomized, double-blind,
placebo-controlled study of clobetasol propionate 0.05% foam in the
treatment of nonscalp psoriasis.” International Journal of Dermatology;
2002; 41:269-274. Retrieved February 2, 2016 from http://www.readcube.com/articles/10.1046/j.1365-4362.2002.01431.x
2 Weindl, G., Schaller, M., Schaefer-Korting, M., Korting, H. C.“Hyaluronic acid in the treatment and prevention of skin diseases: molecular, biological, pharmaceutical and clinical aspects.” Skin Pharmacol and Physiol; 2004;17:207-213.
Statements made in this news release may be forward-looking and therefore subject to various risks and uncertainties. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in the Company's Annual Information Form, Form 40-F and other filings with Canadian and U.S. securities regulatory authorities. These factors include, but are not limited to, our ability to enter into in-licensing, development, manufacturing and marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our dependency on three products; integration difficulties and other risks if we acquire or in-license technologies or product candidates; reliance on third parties for the marketing of our products; the product approval process is highly unpredictable; the timing of completion of clinical trials; reliance on third parties to manufacture our products; we may be subject to product liability claims; unexpected product safety or efficacy concerns may arise; generate revenue from a limited number of distribution and supply agreements; the pharmaceutical industry is highly competitive; requirements for additional capital to fund future operations; dependence on key managerial personnel and external collaborators; no assurance that we will receive regulatory approvals in the U.S., Canada or any other jurisdictions; limitations on reimbursement in the healthcare industry; limited reimbursement for products by government authorities and third-party payor policies; various laws pertaining to health care fraud and abuse; reliance on the success of strategic investments and partnerships; the publication of negative results of clinical trials; unpredictable development goals and projected time frames; rising insurance costs; ability to enforce covenants not to compete; risks associated with the industry in which it operates; foreign currency risk; the potential violation of intellectual property rights of third parties; our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our products; changes in U.S., Canadian or foreign patent law; litigation in the pharmaceutical industry concerning the manufacture and supply of novel versions of existing drugs that are the subject of conflicting patent rights; inability to protect our trademarks from infringement; shareholders may be further diluted; volatility of our share price; a significant shareholder; we do not currently intend to pay dividends; and our operating results may fluctuate significantly; we may be unsuccessful in evaluating material risks involved in complete and future acquisitions; we may be unable to identify, acquire or integrate acquisition targets successfully; operations in the U.S.; and inability to meet covenants on our credit facilities. All forward-looking statements presented herein should be considered in conjunction with such filings. Except as required by Canadian or U.S. securities laws, the Company does not undertake to update any forward-looking statements; such statements speak only as of the date made.